Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab ... 7thSpace Interactive (press release) In clinical and experimental settings, antibody-based anti-CD20/rituximab and small molecule proteasome inhibitor (PI) bortezomib (BTZ) treatment proved effective modalities for B cell depletion in lymphoproliferative disorders as well as autoimmune ... |
